Market Place
Sourcing Support
ArriVent Announces Positive Data For Firmonertinib
09 Sep 2024 //
GLOBENEWSWIRE
Aarvik Therapeutics Announces Option Exercise By Partner ArriVent BioPharma
15 Aug 2024 //
BUSINESSWIRE
ArriVent licenses ADC from $100M biobuck deal with Aarvik
15 Aug 2024 //
FIERCE BIOTECH
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
14 Aug 2024 //
GLOBENEWSWIRE
ArriVent To Present Firmonertinib Data At World Lung Cancer Conference
12 Aug 2024 //
GLOBENEWSWIRE
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
06 Jun 2024 //
BIOSPACE
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
05 Jun 2024 //
GLOBENEWSWIRE
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
16 May 2024 //
GLOBENEWSWIRE
ArriVent Appoints Kristine Peterson to its Board of Directors
22 Apr 2024 //
GLOBENEWSWIRE
ArriVent brings in $175M for biotech’s second IPO of the year
26 Jan 2024 //
FIERCE BIOTECH
ArriVent Announces Pricing of Upsized Initial Public Offering
25 Jan 2024 //
PRESS RELEASE
Arrivent unveils $135M IPO pricing to get furmonertinib to FDA
22 Jan 2024 //
FIERCE BIOTECH
Metagenomi, Arrivent to sneak through crack in IPO window
07 Jan 2024 //
FIERCE BIOTECH
ArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer
05 Jan 2024 //
GLOBENEWSWIRE
ArriVent files for IPO, raising funds as it takes PIII cancer drug through trial
05 Jan 2024 //
ENDPTS
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib
30 Oct 2023 //
GLOBENEWSWIRE
ArriVent Appoints Chris Nolet to its Board of Directors
20 Sep 2023 //
GLOBENEWSWIRE
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
27 Mar 2023 //
GLOBENEWSWIRE
With one of biotech`s largest private rounds in a year, ArriVent enters PhIII
27 Mar 2023 //
ENDPTS
Scoop: Bing Yao’s ArriVent lining up $145M raise, after $150M debut in 2021
03 Jan 2023 //
ENDPTS
ArriVent Bio Begins Enrollment in Global PIb Trial of Furmonertinib in NSCLC
05 Jul 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.